Royal DSM announced it has entered into an exclusive commercial partnership with global leader and pioneer in cannabinoid active pharmaceutical ingredients (APIs), Brains Bioceutical. The partnership extends DSM's capabilities as a purpose-led innovation partner in the pharmaceutical market – creating a platform from which it can enable agile early-stage drug development to unlock and deliver value-added cannabinoid-based products that benefit global patient health. Together, DSM and Brains Bioceutical are strategically positioned to lead the development of cannabinoid based pharmaceutical products, using Brains' EU-GMP APIs. The cannabinoid API market is fast-growing, powered by strong scientific evidence demonstrating the potential of cannabinoid in several therapeutic areas, including Central Nervous System (CNS) diseases. CNS diseases – a broad category of neurological conditions including epilepsy, Alzheimer's disease, Parkinson's disease, and stroke – are increasingly recognized as one of the most prevalent disorders worldwide with a high burden to patients. With positive findings in more than 160 clinical trials to date, there is an opportunity to create a new platform that will support pharmaceutical manufacturers in the development of bespoke cannabinoid-based drug products that expand treatment possibilities. Enabled by Brains Bioceutical's leading portfolio of naturally-sourced, EU-GMP cannabinoid APIs – registered with the UK Medicines and Healthcare products Regulatory Agency (MHRA) and with a filed Drug Master File (DMF) with the Food and Drug Administration (FDA) in the USA - and extensive expertise in the sector, the partnership will see DSM apply its science and marketing capabilities to bring the highest quality cannabinoid APIs to customers, with the capability to manufacture custom cannabinoids. This will create new innovation opportunities for prescription drug (Rx) manufacturers and enable them to enter the cannabinoid market with confidence. Brains Bioceutical is the ideal partner due to its extensive EU-GMP certified cannabinoid manufacturing capabilities and unparalleled expertise in the cannabis and hemp sectors. As one of the only companies worldwide to provide a secure supply of standardized API cannabinoids of natural origin, Brains Bioceutical is setting the global standard for cannabinoid API innovation. The investment and strategic transaction solidify the position of Brains Bioceutical as one of the leading pharmaceutical companies in the CBD sector and will allow it to take advantage of strategic partnerships that DSM has developed.